NANOBIOTIX Signs a License Agreement with Janssen to Co-Develop and Commercialize NBTXR3
Shots:
- NANOBIOTIX will receive $60M in near-term cash & operational support incl. $30M up front & ~$30M in regulatory & development support for the (NANORAY-312) study, ~$1.8B in milestones & an additional development & regulatory milestone of ~$650M for 5 new indications, ~$220M as per indication, $30 million in equity investments along with royalties
- Janssen to get a license globally for the development & commercialization of NBTXR3 & will lead an initial P-II study of NBTXR3 for stage three lung cancer & also get the rights to control studies currently led by NANOBIOTIX
- NANOBIOTIX will maintain operational control of (NANORAY-312) & other ongoing studies along with NBTXR3 manufacture, clinical supply, & initial commercial supply. NBTXR3 is being studied in multiple studies across solid tumor
Ref: Globenewswire | Image: Nanobiotix
Related News:- Nanobiotix Collaborates with Lianbio to Develop and Commercialize NBTXR3 in China and other Asian Countries
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
